A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.
This is a randomized, Open-label, Phase Ib/IIa study to evaluate the efficacy and safety of SPH4336 monotherapy or in combination with Cadonilimab in the patients with selected advanced solid tumors.
Advanced Solid Tumors
DRUG: SPH4336|DRUG: Cadonilimab
Progression-free survival (PFS), From the start date of study treatment to the date of progression disease or death , whichever occurred first., Approximately 2 years
Objective response rate (ORR), Tumor response will be evaluated according to the Response Evaluation Criteria Solid Tumors (RECIST) criteria version 1.1., Approximately 2 years|progression-free rate（PFR）, Proportion of subjects who were alive and free of disease progression from the first use of the investigational drug to 12 weeks., Approximately 2 years|Cmax, PK (Pharmacokinetics) parameters., Approximately 2 years|Tmax, PK (Pharmacokinetics) parameters., Approximately 2 years|Disease control rate (DCR), DCR was defined as the percentage of patients who have achieved complete response, partial response and stable disease., Approximately 2 years|Duration of remission (DOR), DOR was defined for participants who had an objective response as the time from the first occurrence of a documented unconfirmed response to the date of disease progression per RECIST v1.1 or death from any cause., Approximately 2 years|Overall Survival (OS), Determination of the overall survival times of all patients., Approximately 8 years|Incidence of Adverse event, Safety and tolerability, Approximately 2 years
This is a randomized, Open-label, Phase Ib/IIa study to evaluate the efficacy and safety of SPH4336 monotherapy or in combination with Cadonilimab in the patients with selected advanced solid tumors.